FDA threatens Ocugen with $10,000 fine for failing to report study resultsnews2022-04-26T11:35:18+00:00April 26th, 2022|Fierce Pharma|
Novartis hires seasoned Wall Street analyst Ronny Gal as new M&A czarnews2022-04-26T07:02:05+00:00April 26th, 2022|Fierce Pharma|
GSK’s ViiV, Pfizer and Roche’s Genentech earn top ranks among patient advocacy groupsnews2022-04-26T01:36:12+00:00April 26th, 2022|Fierce Pharma|
FDA expands approval of Gilead’s Veklury, providing young children their first COVID treatment optionnews2022-04-25T19:32:17+00:00April 25th, 2022|Fierce Pharma|
FDA plans study into how patients and physicians make prescription decisionsnews2022-04-25T18:38:32+00:00April 25th, 2022|Fierce Pharma|
Roche delays Polivy’s blockbuster lymphoma filing as FDA asks for more datanews2022-04-25T14:37:54+00:00April 25th, 2022|Fierce Pharma|
Ardelyx’s Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanornews2022-04-25T13:34:33+00:00April 25th, 2022|Fierce Pharma|
Is AstraZeneca finally ready to score with underachieving cancer drug tremelimumab?news2022-04-25T13:33:09+00:00April 25th, 2022|Fierce Pharma|
Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansionnews2022-04-25T13:12:26+00:00April 25th, 2022|Fierce Pharma|
Pfizer’s blood pressure med recall creeps into US as testing flags carcinogen threatnews2022-04-25T11:58:37+00:00April 25th, 2022|Fierce Pharma|
